Johnson & Johnson (JNJ) Declares $1.24 Quarterly Dividend; 3.3% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
July 18, 2024 6:14 AM EDTRBC Capital analyst Shagun Singh reiterated an Outperform rating and $175.00 price target on Johnson & Johnson (NYSE: JNJ).
The analyst comments "JNJ's stock traded higher (+3.7%) post-Q2'24 beat. It maintained its FY24 adjusted operational sales growth outlook but lowered adjusted EPS to reflect M&A-related... More
Johnson & Johnson (JNJ) PT Raised to $160 at Stifel
July 17, 2024 1:58 PM EDTStifel analyst Rick Wise raised the price target on Johnson & Johnson (NYSE: JNJ) to $160.00 (from $155.00) while maintaining a Hold rating.
The analyst comments "Offsetting concerns about China and competitive pressures, JNJs robust Innovative Medicine (65.5% of sales, +8.8% y/y) performance reiterated a still-positive 2H24 growth... More
Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates
July 17, 2024 6:39 AM EDTJohnson & Johnson (NYSE: JNJ) reported a robust second quarter, with both earnings and revenue surpassing Wall Street estimates.
The healthcare giant posted adjusted earnings per share (EPS) of $2.82, exceeding analyst predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.
This performance represents a 4.3% increase in reported sales growth, with an operational growth of 6.6%.
The company's stock responded positively to the news, with shares rising 2.1% as investors reacted favorably... More
